A framework for genomic biomarker actionability and its use in clinical decision making

The increasing scope and availability of genetic testing options for patients suffering from cancer has raised questions about how to use results of molecular diagnostics to inform patient care. For some biomarkers (e.g. BRAF mutations in melanoma), standards exist that outline treatments for indivi...

Descripción completa

Detalles Bibliográficos
Autores: Vidwans, Smruti J., Turski, Michelle L., Janku, Filip, Garrido-Laguna, Ignacio, Munoz, Javier, Schwab, Richard, Subbiah, Vivek, Rodón Ahnert, Jordi, Kurzrock, Razelle
Tipo de recurso: artículo
Fecha de publicación:2014
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:185238
Acceso en línea:https://ddd.uab.cat/record/185238
https://dx.doi.org/urn:doi:10.18632/oncoscience.90
Access Level:acceso abierto
Palabra clave:Biomarker
Clinical decision making
Targeted therapies
Predictive biomarkers
id ES_4e57d2a2268d2004db2d138cf2849302
oai_identifier_str oai:ddd.uab.cat:185238
network_acronym_str ES
network_name_str España
repository_id_str
spelling A framework for genomic biomarker actionability and its use in clinical decision makingVidwans, Smruti J.Turski, Michelle L.Janku, FilipGarrido-Laguna, IgnacioMunoz, JavierSchwab, RichardSubbiah, VivekRodón Ahnert, JordiKurzrock, RazelleBiomarkerClinical decision makingTargeted therapiesPredictive biomarkersThe increasing scope and availability of genetic testing options for patients suffering from cancer has raised questions about how to use results of molecular diagnostics to inform patient care. For some biomarkers (e.g. BRAF mutations in melanoma), standards exist that outline treatments for individuals harboring aberrations in the biomarker; however for the vast majority of genomic abnormalities, few guidelines exist. Clinical decision making and the therapeutic approach for a patient with a given cancer characterized by aberrations in different genes may be aided by the use of a biomarker actionability framework that provides levels of evidence regarding whether and how a molecular abnormality can be considered a therapeutically relevant biomarker. A gene may be considered theoretically actionable if it has a basis of actionability, such that clinically available drugs can target a gene product that drives the cancer or is differentially expressed in tumor versus normal elements. Herein, we discuss a possible framework for developing guidelines for actionability, as they relate to genomically-based cancer therapeutics.Universitat Autònoma de Barcelona 22014-01-0120142014-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/185238https://dx.doi.org/urn:doi:10.18632/oncoscience.90reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:1852382026-06-06T12:50:31Z
dc.title.none.fl_str_mv A framework for genomic biomarker actionability and its use in clinical decision making
title A framework for genomic biomarker actionability and its use in clinical decision making
spellingShingle A framework for genomic biomarker actionability and its use in clinical decision making
Vidwans, Smruti J.
Biomarker
Clinical decision making
Targeted therapies
Predictive biomarkers
title_short A framework for genomic biomarker actionability and its use in clinical decision making
title_full A framework for genomic biomarker actionability and its use in clinical decision making
title_fullStr A framework for genomic biomarker actionability and its use in clinical decision making
title_full_unstemmed A framework for genomic biomarker actionability and its use in clinical decision making
title_sort A framework for genomic biomarker actionability and its use in clinical decision making
dc.creator.none.fl_str_mv Vidwans, Smruti J.
Turski, Michelle L.
Janku, Filip
Garrido-Laguna, Ignacio
Munoz, Javier
Schwab, Richard
Subbiah, Vivek
Rodón Ahnert, Jordi
Kurzrock, Razelle
author Vidwans, Smruti J.
author_facet Vidwans, Smruti J.
Turski, Michelle L.
Janku, Filip
Garrido-Laguna, Ignacio
Munoz, Javier
Schwab, Richard
Subbiah, Vivek
Rodón Ahnert, Jordi
Kurzrock, Razelle
author_role author
author2 Turski, Michelle L.
Janku, Filip
Garrido-Laguna, Ignacio
Munoz, Javier
Schwab, Richard
Subbiah, Vivek
Rodón Ahnert, Jordi
Kurzrock, Razelle
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Biomarker
Clinical decision making
Targeted therapies
Predictive biomarkers
topic Biomarker
Clinical decision making
Targeted therapies
Predictive biomarkers
description The increasing scope and availability of genetic testing options for patients suffering from cancer has raised questions about how to use results of molecular diagnostics to inform patient care. For some biomarkers (e.g. BRAF mutations in melanoma), standards exist that outline treatments for individuals harboring aberrations in the biomarker; however for the vast majority of genomic abnormalities, few guidelines exist. Clinical decision making and the therapeutic approach for a patient with a given cancer characterized by aberrations in different genes may be aided by the use of a biomarker actionability framework that provides levels of evidence regarding whether and how a molecular abnormality can be considered a therapeutically relevant biomarker. A gene may be considered theoretically actionable if it has a basis of actionability, such that clinically available drugs can target a gene product that drives the cancer or is differentially expressed in tumor versus normal elements. Herein, we discuss a possible framework for developing guidelines for actionability, as they relate to genomically-based cancer therapeutics.
publishDate 2014
dc.date.none.fl_str_mv 2
2014-01-01
2014
2014-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/185238
https://dx.doi.org/urn:doi:10.18632/oncoscience.90
url https://ddd.uab.cat/record/185238
https://dx.doi.org/urn:doi:10.18632/oncoscience.90
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407749975048192
score 15.301629

Similares en LA Referencia